Tafinlar 75 mg (Dabrafenib 75 mg) by Novartis.
Indications: BRAF V600 mutation-positive melanoma, NSCLC and anaplastic thyroid cancer, in combination with trametinib.
Administration: Oral: 150 mg (2 capsules) twice daily, on an empty stomach.
Storage: Store below 25–30 °C in the original package. Keep out of the sight and reach of children.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Novartis |
| Active ingredient | Dabrafenib 75 mg (as mesilate) per capsule — BRAF inhibitor. |
| Strength & pack | 120 hard capsules. |
| Form | Hard capsules |
| Storage | Store below 25–30 °C in the original package. Keep out of the sight and reach of children. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |